Cargando…
The Price of Progress: Cost, Access, and Adoption of Novel Cardiovascular Drugs in Clinical Practice
PURPOSE OF REVIEW: The launch of new effective and safe cardiovascular drugs has produced large gains in health outcomes for several cardiovascular conditions. But this innovation comes at the cost of rapidly increasing pharmaceutical spending and high out-of-pocket costs. RECENT FINDINGS: In the US...
Autores principales: | Varghese, Merilyn S., Liu, Chia-Liang, Kazi, Dhruv S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8486158/ https://www.ncbi.nlm.nih.gov/pubmed/34599393 http://dx.doi.org/10.1007/s11886-021-01598-w |
Ejemplares similares
-
Promise and Perils of Telehealth in the Current Era
por: Mahtta, Dhruv, et al.
Publicado: (2021) -
Can Sound Public Health Policies Stem the Tide of Burgeoning Epidemic of Cardiovascular Disease in South Asians?
por: Shams, Pirbhat, et al.
Publicado: (2021) -
COVID’s Impact on Non-communicable Diseases: What We Do Not Know May Hurt Us
por: Gordon Patti, Karl, et al.
Publicado: (2022) -
Impact of COVID-19 on Management Strategies for Coronary and Structural Heart Disease Interventions
por: Ya’Qoub, Lina, et al.
Publicado: (2022) -
Ischemia Trial: Does the Cardiology Community Need to Pivot or Continue Current Practices?
por: Jafary, Fahim H., et al.
Publicado: (2022)